RMD1202

**RMD1202** is a first-in-class, single-injection gene therapy developed by Remedium Bio using the proprietary **Prometheus™** platform for the treatment of **obesity** and **type 2 diabetes**. It delivers continuous subcutaneous production of a **GLP-1 receptor agonist** with zero-order kinetics, matching or exceeding the efficacy of daily exenatide injections in preclinical high-fat diet and streptozotocin-induced models of late-stage type 2 diabetes, including significant weight loss, improved glucose tolerance, and insulin sensitivity. The approach eliminates pharmacokinetic spikes associated with repeated protein injections, potentially reducing gastrointestinal side effects and improving tolerability, while enabling post-administration dose adjustment via pharmacological or physical methods for durable, localized expression without antigenicity.[1][2][3]